GlassScriptPhysician profile
Jaime Rosa
NPI 1922081611
$865.57
in general payments reported to CMS, 2019-2025
9 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $51.45 · 2021: $110 · 2022: $22.16 · 2023: $128 · 2024: $74.08 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $322.73 | 2019-2025 | Crexont, Rytary |
| Greenwich Biosciences, INC. | $159.88 | 2019-2021 | |
| Ucb, INC. | $134.07 | 2019-2020 | |
| Pbg Puerto Rico LLC | $97.08 | 2023-2025 | |
| Abbvie INC. | $45.84 | 2024-2025 | |
| Medtronic, INC. | $45.71 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.16 | 2022 | |
| Pfizer Pharmaceuticals LLC | $20.00 | 2019 | |
| Acadia Pharmaceuticals INC | $18.10 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Rosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.